Physiologically active polypeptide conjugate having prolonged in vivo half-life
US8163889B2 · kind B2 · utility
8Cited by
8References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 22, 2009 |
| Grant date | Apr 24, 2012 |
| Priority date | — |
| Expiry date | Oct 22, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/6883
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A protein conjugate having a prolonged in vivo half-life of a physiological activity, comprising i) a physiologically active polypeptide, ii) a non-peptidic polymer, and iii) an immunoglobulin, is useful for the development of a polypeptide drug due to the enhanced in vivo stability and prolonged half-life in blood, while reducing the possibility of inducing an immune response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.